Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collabor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S. G. P. Funnell, W. E. Dowling, C. Muñoz-Fontela, P.-S. Gsell, D. E. Ingber, G. A. Hamilton, L. Delang, J. Rocha-Pereira, S. Kaptein, K. H. Dallmeier, J. Neyts, K. Rosenke, E. de Wit, H. Feldmann, P. Maisonnasse, R. Le Grand, M. B. Frieman, C. M. Coleman
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/16f0fbaa1ef74b81ae8f7a0d0a46c7fa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Ejemplares similares